

## Lumina at ISPOR 2026

From the use of real-world evidence to incorporating patient perspectives, our experts are shaping conversations that drive better healthcare decisions.

Philadelphia  
May 17-20  
Booth #624

### Short Course

**Sunday, May 17**  
13:00 – 17:00 (EDT)

Using RWE to Inform the Value and Affordability Assessment of Cell and Gene Therapies

**Daniel Gladwell**, Antal T Zemplenyi, Oriol de Sola-Morales, Renske MT ten Ham

### Exhibit Hall Theater

**Monday, May 18**  
15:30 – 16:00 (EDT)

Optimizing IEGPs: How HEOR Leadership and Strategic Planning Drive Better Outcomes

Moderator: **Jonathan Kowalski**

Speakers: **Meena Venkatachalam**,  
Chris Leo Pashos

### Posters

**Poster Session 1**  
Monday, May 18 | 10:30 – 13:30 (EDT)

The Impact of Different Time-Varying Network Meta-Analysis Methods to Assess Talazoparib + Enzalutamide versus Olaparib + Abiraterone in Metastatic Castration-Resistant Prostate Cancer

Melissa Kirker, Neo Su, Jack Said, **Adam Gough**, **Emma Tyas**, **Hannah Kilvert**, **Atharva Phadke**, **Amy Barber**, **Yang Meng**

Patient Descriptions of Improved Ability to Self-Regulate Blood Sugar Levels in a Phase 3 Trial of DTX401 for Glycogen Storage Disease Type Ia

Diane M. Turner-Bowker, Shayna Egan, **Blaise Cureg**, **Adriana Voci**, Monica Boyer, Jessica Butler, Richard Collis, Elizabeth Dorn, Kristin Voorhees, **Martha Gauthier**

Reporting and Interpretation of Cognitive Debriefing Results in Patient Reported Outcome Measure Validation: Are There Standards?

**Nathan Johnson**, **Martha Gauthier**, **Julie Whyte**

**Poster Session 2**  
Monday, May 18 | 16:00 – 19:00 (EDT)

Cost-Effectiveness of Recombinant Human C1 Esterase Inhibitor (rhC1-INH) vs Sebetralstat for the Treatment of Severe or Very Severe Hereditary Angioedema (HAE) Attacks

Raffi Tachdjian, Nihal Narsipur, **Yang Meng**, **Spencer Notinger**, **Sarah Brand-Wiita**, Jonathan A. Bernstein, Amanda Harrington

*Top 5% Finalist for the ISPOR 2026 Research Presentation Award*

Defining Curative Potential in Early-Stage Melanoma: Where Physicians and Payers Align and Where They Don't

Christopher Black, Ian Daniel, Jennifer Sander, Sophie Boukouvalas, Oriana Ciani, **Ron Akehurst**, Heather Shaw

Does Your 1 Million Member Cohort Tell the Whole Story? Rethinking Eligible Population Estimation in Chronic Disease Budget Impact Analyses in the US

**Annika Bjerke**, **Tyler Mantaian**, **Yang Meng**

Evaluating the Patient Burden Associated With Delayed Reimbursement: A Case Study of Pembrolizumab in the Treatment of Endometrial Cancer in Canada

**Megan Harmer**, Vimalanand Prabhu, **Edward Church**, Rohit Mistry, Yi Hsuan Chen, **Karl Patterson**, **Matthew Madin-Warburton**, Cedric Joyal, Robin Meng, Micheal Drummond

Patient Descriptions of the Benefits of a Reduced Cornstarch Dose Regimen in a Phase 3 Trial of DTX401 for Glycogen Storage Disease Type IA

Diane M. Turner-Bowker, Shayna Egan, **Blaise Cureg**, **Adriana Voci**, Carolina Fischinger Moura de Souza, Jessica Butler, Richard Collis, Elizabeth Dorn, Kavitha Karnati, Kristin Voorhees, **Martha Gauthier**

### Poster Session 3

Tuesday, May 19 | 10:30 – 13:30 (EDT)

An Expanded Analysis of Which Features Convey Empathy to Patients in Scientific Writing

**Martha Gauthier**, Brandon Foster, Susan Daniels, Laura Watts

---

Beyond “Cured”: Preferred Terminology, Milestones, and Evidence for Payer Decision-Making in Early-Stage Melanoma

Christopher Black, Sophie Boukouvalas, Ian Daniel, Jennifer Sander, Oriana Ciani, Heather Shaw, **Ron Akehurst**

---

Economic Impact of Early Diagnosis and Treatment for Inborn Errors of Immunity with focus on common variable immunodeficiency (CVID) in Spain: A Cost-Effectiveness Perspective

Batyrkhan Kumatov, **Annaëlle Vinzent**, Alessandro Catanzaro, Melike Inkaya Taskin, Jonathan Galduf, **Chrissy Lowry**, Dr Pere Soler-Palacin

### Poster Session 4

Tuesday, May 19 | 16:00 – 19:00 (EDT)

Real World Evidence for Label Expansion: Identifying Off-Label Use Trends in the Hospital Setting

**Josine Kuiper\***, **Jetty Overbeek\***, **Nikita Jeswani**

---

\*PHARMO, Part of Lumanity

---

The HERCULES Study: Methods and Rationale of Assessing the Health-Related Quality of Life (HRQoL) in Patients Living with Early-Stage Chronic Kidney Disease and Their Carers in the US

Villum Wittrup-Jensen, John F. Bridges, **Jason Hyman**, **Brandon Foster**, Sean Delaney, Nicole Puetz, Silvia Scalabrini, **Nathan Johnson**, Kevin F. Erickson

### Poster Session 5

Wednesday, May 20 | 16:00 – 19:00 (EDT)

Inclusion of Patient-Reported Outcome Measures for Pediatric Versus Adult Populations in FDA Biological and Novel Drug Therapy Approvals from 2021-2025

**Laura Tesler Waldman**, **Kathy Vong**, **Marc Bacharach**, **Martha Gauthier**